Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Switzerland
/
Pharmaceuticals & Biotech
Create a narrative
Bachem Holding
SWX:BANB Community
1
Narratives
written by author
0
Comments
on narratives written by author
6
Fair Values set
on narratives written by author
Create a narrative
Bachem Holding
Popular
Undervalued
Overvalued
Bachem Holding
WA
Analyst Price Target
Consensus Narrative from 7 Analysts
Building K And 24-Hour Operations Will Improve Efficiency
Key Takeaways Capacity expansion and 24/7 operations enhance production, reduce costs, and bolster revenue growth in response to rising demand for peptides and oligonucleotides. Strategic investments and innovations in API production and U.S. market expansion are expected to sustain revenue growth and optimize margins in expanding pharmaceutical sectors.
View narrative
CHF 75.57
FV
26.2% undervalued
intrinsic discount
22.69%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Your Valuation for
BANB
Bachem Holding
Your Fair Value
CHF
Current Price
CHF 55.75
50.3% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
1b
2015
2018
2021
2024
2025
2027
2030
Revenue CHF 1.5b
Earnings CHF 291.2m
Advanced
Set as Fair Value